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Background. We aimed to explore the prognostic impact of the hypoxia-induced factors (HIFαs) 1 and 2, the metabolic HIF-
regulated glucose transporter GLUT-1, and carbonic anhydrase IX (CAIX) in non-gastrointestinal stromal tumor soft tissue
sarcomas(non-GISTSTS).Methods. Duplicate coreswithviabletumortissuefrom206patientswithnon-GISTSTSwereobtained
and tissue microarrays were constructed. Immunohistochemistry (IHC) was used to evaluate expression of hypoxic markers.
Results. In univariate analyses, GLUT-1 (P<0.001) and HIF-2α (P = 0.032) expression correlated signiﬁcantly with a poor
disease-speciﬁc survival (DSS). In the multivariate analysis, however, only high expression of GLUT-1 (HR 1.7, CI 95% 1.1–2.7,
P = 0.021) was a signiﬁcant independent prognostic indicator of poor DSS. Conclusion. GLUT-1 is a signiﬁcant independent
negative prognostic factor in non-GIST STS.
1.Background
Adaptationoftumorcellstohypoxiaiscriticalfortumorsur-
vival and progression [1]. Tumor hypoxia leads to resistance
to radiotherapy and chemotherapy and is associated with an
increased metastatic potential [2, 3]. In soft tissue sarcomas
(STS) hypoxia has been found to be related to reduced
disease-free survival [4] and increased cell proliferation [5].
Principally there are three methods of measuring
hypoxia, directly in vivo through microelectrodes (e.g.,
Eppendorf pO2 Histograph), visualization of nitroimidazole
compounds by PET, or in tumor tissue by studying endoge-
nous markers of hypoxia [6]. HIF-1, GLUT-1, and CAIX
have been proposed as endogenous immunohistochemical
(IHC) markers of hypoxia [7, 8] although this is a matter of
controversy [9, 10].
Since Semenza et al. discovered HIF-1α in 1992, the
hypoxia inducible factors (HIFs) have been identiﬁed as
key regulators of genes involved in hypoxic responses
[11]. Except for diﬀerences in distribution, abundance, and
expression in response to prolonged hypoxia, the regulatory
characteristics are quite similar among HIFs [12–15]. IHC
assessments in human cancer biopsies have found elevated
levels of HIF-1α and/or HIF-2α protein in the majority of
primary human cancers and their metastases [16]. Further-
more, clinical data shows that increased levels of HIF-1α and
HIF-2α are associated with higher patient mortality in many
human cancers [17].
Cancer cells prefer glycolysis with or without hypoxia
[18]. The HIF-regulated glucose transporter GLUT-1 facil-
itates increased inﬂux of glucose and is upregulated in
hypoxic conditions. GLUT-1 is overexpressed in several
tumors [19, 20], and increased expression of GLUT-1
appears to be correlated with a poor prognosis in a variety
of tumors [21–23]. CAIX mediates the extracellular trapping
of acidity. Together with GLUT-1, it is among the most
critical molecules, for maintaining ATP levels with stable
intracellular pH, needed for cancer cell survival [24–26].
Hypoxia-related markers are inadequately explored in STS,
and the data are diverging. Hence, further knowledge on the
molecular mechanisms in this tumor entity is warranted.2 Sarcoma
As the prognosis of patients with STS is still unsat-
isfactory [27], new therapeutic targets are highly desired.
The remarkable history of imatinib in CD 117 positive
GIST patients is inspiring [28]. The evaluation of potential
prognostic molecular markers may help to identify both
promisingtargetsandpatientsinneedofadjuvanttreatment.
As a consequence, it is important to enhance our knowledge
about pivotal molecular markers with inherent and diverse
signiﬁcant prognostic relevance for tumor progression and
survival.
We have previously reported on the prognostic impact of
various angiogenic factors in sarcoma [29]. Herein, using a
high-throughput TMA technique, we explore the prognostic
impact of markers associated with hypoxia (HIF1α,H I F 2 α)
and related metabolic markers (GLUT-1, CAIX) in non-
GIST STS.
2.MaterialsandMethods
2.1. Patients and Clinical Samples. Primary tumor tissues
from anonymized patients diagnosed with non-GIST STS at
the University Hospital of North Norway and the Hospitals
of Arkhangelsk county, Russia, from 1973 through 2006,
were collected. In total 496 patients were registered from
the hospital databases. Of these 290 patients were excluded
from the study because of: missing clinical data (n = 86),
inadequate paraﬃn-embedded ﬁxed tissue blocks (n = 161),
or metastasis at the time of diagnosis (n = 43). Thus 206
patients were included in this study.
This report includes followup data as of September 2009.
The median follow-up was 37.6 (range 0.1–391.7) months.
Complete demographic and clinical data were collected ret-
rospectively. Formalin-ﬁxed and paraﬃn-embedded tumor
specimens were obtained from the archives of the Depart-
ments of Pathology at the University Hospital of North
Norway and the Hospitals of Arkhangelsk county, Russia.
The tumors were graded according to the French F´ ed´ eration
Nationale des centres de Lutte Contre le Cancer (FNCLCC)
system and histologically subtyped according to the World
Health Organization guidelines [30, 31]. Wide resection
margins were deﬁned as wide local resection with free
microscopic margins or amputation of the aﬀected limb or
organ. Nonwide resection margins were deﬁned as marginal
or intralesional resection margins, or no surgery.
2.2. Microarray Construction. A l ls a r c o m a sw e r eh i s t o l o g i -
cally reviewed by two trained pathologists (S. Sorbye and
A. Valkov), and the most representative areas of tumor
cells (neoplastic mesenchymal cells) were carefully selected
and marked on the hematoxylin and eosin (H/E) slide
and sampled for the tissue microarray (TMA) blocks. The
TMAs were assembled using a tissue-arraying instrument
(Beecher Instruments, Silver Springs, MD). The detailed
methodology has been previously reported [32]. Brieﬂy, we
used a 0.6mm diameter stylet, and the study specimens were
routinely sampled with duplicate cores from diﬀerent areas
of neoplastic tissue. Normal soft tissues were used as staining
controls.
To include all core samples, 12 TMA blocks were con-
structed. Multiple 4μm sections were cut with a Micron
microtome (HM355S) and stained by speciﬁc antibodies for
IHC analysis.
2.3. Immunohistochemistry. All applied antibodies had been
subjected to in-house validation by the manufacturer for
IHC on paraﬃn-embedded material. All sections were de-
paraﬃnised with xylene and rehydrated with ethanol.
The 4μm sections, containing tissue cores, were subjected
to the following antibodies: HIF1α (mouse monoclonal,
NB100-131, Novus Biologicals,1:3500), HIF2α (rabbit poly-
clonal, ab199, Abcam,1:40), GLUT-1 (mouse monoclonal,
AB40084, Abcam,1:500), and CAIX (rabbit polyclonal,
ab15086, Abcam,1:200).
CAIX, GLUT-1, and the HIFs were stained using the
Ventana Benchmark XT (Ventana Medical Systems Inc.),
procedure ultraview DAB. Antigen retrieval was done auto-
matic by Cell Conditioning Solution (CC1) mild (30min for
CAIX and HIFs and 1 hour for GLUT-1).
The primary antibody was visualized by adding a sec-
ondary antibody conjugated with Biotin, followed by an
Avidin/Biotin/Peroxydase complex (Vectastain ABC Elite kit
from Vector Laboratories). Finally, all slides were counter-
stained with hematoxylin to visualize the nuclei.
2.4. Scoring of Immunohistochemistry. The ARIOL imaging
system (Genetix, San Jose, CA) was used to scan the slides
of antibody staining of the TMAs. The slides were loaded in
the automated slide loader (Applied Imaging SL 50), and the
specimens were scanned at low resolution (1.25x) and high
resolution (20x) using the Olympus BX 61 microscope with
an automated platform (Prior). Representative and viable
tissue sections were scored manually and semiquantitatively
on the computer screen. HIF-1α showed in most cases cyto-
plasmic staining or cytoplasmic and nuclear staining. For
HIF-2α nuclear, or nuclear and weak cytoplasmic staining
wasrecorded.Although it is suggestedthat nuclear HIF is the
active form, it is synthesized and degraded in the cytoplasm.
Hence, there may be some redistribution explaining both
nuclear and cytoplasmic staining. However, the overall
expression indicates upregulation of the pathway [16, 33].
GLUT-1 and CAIX antibodies usually recognize membrane-
bound proteins [34–36], at least on cells of epithelial origin.
But in our study, GLUT-1 showed cytoplasmic staining,
and in a few cases both cytoplasmic and nuclear staining.
For CAIX cytoplasmic staining was evaluated (Figure 1).
Whether this is due to true diﬀerences between sarcomas
and epithelial tumors, or that sarcoma cells with scanty
cytoplasm render the identiﬁcation of membrane staining
diﬃcultonthebackgroundofastrongcytoplasmicreactivity,
remains unclear [37–39].
The dominant staining intensity was scored as: 0 =
negative; 1 = weak; 2 = intermediate; 3 = strong. All samples
were anonymized and independently scored by two trained
pathologists (A. Valkov and S. Sorbye). When assessing a
variable for a given core, the observers were blinded to the
scores of the other variables and to outcome.Sarcoma 3
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Figure 1: Immunohistochemical analysis in non-GIST STS representing negative, and score 1–3 of CAIX, GLUT-1, HIF-1α, and HIF-2α.
non-GIST STS: non-gastrointestinal stromal tumor soft-tissue sarcomas, CAIX: carbonic anhydrase IX, GLUT-1: glucose transporter-1, and
HIF-1/2α: hypoxia induced factor 1/2α.
In case of disagreement the slides were reexamined,
and consensus was reached by the observers. Mean score
for duplicate cores from each individual was calculated
separately. High expression was deﬁned as: = 3f o rH I F 1 α;
≥2.5 for HIF2α; ≥2f o rC A I X ;≥1 for GLUT-1 (Figure 1).
2.5. Statistical Methods. All statistical analyses were done
using the statistical package SPSS (Chicago, IL), version
15. The IHC scores from each observer were compared for
interobserver reliability by use of a two-way random eﬀect
model with absolute agreement deﬁnition. The intraclass
correlation coeﬃcient (reliability coeﬃcient) was obtained
from these results. The Chi-square and Fishers Exact tests
were used to examine the association between molecular
marker expression and various clinicopathological param-
eters. Fisher Exact test was used when there was a 2 × 2
table, and the sample size was small (less than 5 in a given
cell). Otherwise chi-square was used. We consider r>0.2a s
potentially relevant and due to multiple testing signiﬁcant P
value was set at <0.01 in correlation analyses.
Univariate analyses were done using the Kaplan-Meier
method, and statistical signiﬁcance between survival curves
was assessed by the log rank test. The signiﬁcance level used
for log rank test was P<0.05. DSS was determined from the
dateofdiagnosistothetimeofcancer-relateddeath.Toassess
the independent value of diﬀerent pretreatment variables
on survival, in the presence of other variables, multivariate
analyseswerecarriedoutusingtheCoxproportional hazards
model.Onlyvariablesofsigniﬁcantvaluefromtheunivariate
analyses were entered into the Cox regression analyses.
Probability for stepwise entry and removal was set at .05 and
.10, respectively.
3.EthicalClearance
The National Data Inspection Board and The Regional
(Northern Norway) Committee for Research Ethics
approved the study. The committee classiﬁed the project
as retrospective nontherapeutic, bio- and genetechnology
science on already registered data and archived tumor
material and hence speciﬁcally waived the need for consent.
4. Results
4.1. Clinicopathological Variables. The clinicopathological
variables are summarized in Table 1. The median age was4 Sarcoma
Table 1: Prognostic relevance of clinicopathological variables for disease-speciﬁc survival in 206 non-gastrointestinal stromal tumor soft-
tissue sarcomas (univariate analyses, log rank test, multivariate analyses, Cox proportional hazards model).
Characteristics
Univariate analyses Multivariate analyses∗
Patients
(n)
Patients
(%)
Median survival
(months)
5-year survival
(%)
P HR 95% CI P
Age 0.030 0.121#
≤ 20 years 17 8 41 47 1.000
21–60 years 89 43 NR 61 0.728 0.281–1.889 0.515
>60 years 100 49 52 46 1.222 0.445–3.356 0.698
Gender 0.265
Male 89 43 NR 55
Female 117 57 75 51
Patient nationality 0.014
Norwegian 140 68 NR 58 1.000 0.142
Russian 66 32 39 42 1.453 0.882–2.393
Histological entity 0.003 0.086#
Pleomorphic
sarcoma 54 26 54 48 1.000
Leiomyosarcoma 48 23 89 64 0.595 0.327–1.082 0.089
Liposarcoma 32 16 NR 71 0.411 0.169–0.999 0.050
Fibrosarcoma 16 8 123 56 0.773 0.330–1.808 0.552
Angiosarcoma 10 5 10 30 1.124 0.386–3.276 0.830
Rhabdomyosarcoma 12 6 41 50 0.419 0.156–1.126 0.085
MPNST 9 4 NR 56 0.544 0.162–1.824 0.324
Synovial sarcoma 13 6 31 28 1.257 0.571–2.767 0.570
Sarcoma NOS 12 6 9 25 1.640 0.707–3.805 0.249
Tumor localization 0.805
Extremities 79 38 123 56
Trunk 40 19 44 49
Retroperitoneum 30 15 57 47
Head/neck 16 8 27 47
Visceral 41 20 75 57
Tumor size 0.019 0.061#
≤5cm 60 29 NR 66 1.000
5–10cm 77 37 62 51 1.478 0.825–2.646 0.189
>10cm 67 33 37 44 2.072 1.129–3.801 0.019
Missing 2 1
Malignancy grade <0.001 <0.001#
1 56 27 NR 78 1.000
2 82 40 62 51 2.761 1.352–5.639 0.005
3 68 33 22 34 4.642 2.219–9.710 <0.001
Tumor depth 0.002
Superﬁcial 16 8 NR 93 1.000
Deep 190 92 59 50 7.658 1.043–56.215 0.045
Surgery <0.001
Yes 194 94 123 56 1.000
No 12 6 4 0 16.689 5.776–48.218 <0.001
Resection margins <0.001
Wide 97 47 NR 66 1.000
Nonwide/no surgery 109 53 36 41 1.894 1.214–2.955 0.005Sarcoma 5
Table 1: Continued.
Characteristics
Univariate analyses Multivariate analyses∗
Patients
(n)
Patients
(%)
Median survival
(months)
5-year survival
(%)
P HR 95% CI P
Chemotherapy 0.641
No 166 81 91 54
Yes 40 19 41 47
Radiotherapy 0.224
No 141 69 127 55
Yes 65 32 52 49
NR: not reached; MPNST: malignant peripheral nerve sheath tumor; NOS: not otherwise speciﬁed
∗Only signiﬁcant variables from the univariate analyses were entered into the multivariate analyses
#Overall signiﬁcance as prognostic factor.
60 (range 0–91) years, 57% were female, 140 patients were
Norwegian, and 66 Russian. The non-GIST STSs comprised
206 tumors including angiosarcoma (n = 10), ﬁbrosarcoma
(n = 16), leiomyosarcoma (n = 48), liposarcoma (n =
32), undiﬀerentiated pleomorphic sarcoma (n = 54), neu-
roﬁbrosarcoma/malignant peripheral nerve sheath tumor
(MPNST, n = 9), rhabdomyosarcoma (n = 12), synovial
sarcoma (n = 13), and unspeciﬁed sarcoma (n = 12). The
tumor origins were distributed as follows: 38% extremities,
19% trunk, 15% retroperitoneal, 8% head/neck, and 20%
visceral.
4.2. Interobserver Variability. Interobserver scoring agree-
ment was tested for GLUT-1. The intraclass correlation co-
eﬃcient (r) was 0.88 (P<0.001), indicating good repro-
ducibility between the investigators.
4.3. Expression of Hypoxia-Related Markers and Their Cor-
relations. None of the markers correlated signiﬁcantly with
age, gender, histological subgroup, tumor depth, or tumor
size. High GLUT-1 expression was signiﬁcantly associated
(r = 0.35, P<0.001) with a high histological grade (high
expression: grade I 21.8%, grade II 39.5%, grade III 66.1%).
The same signiﬁcant association (r = 0.23, P = 0.001)
was also found for high HIF-2α expression and histological
grade (high expression: grade I 49.1%, grade II 71.3%, Grade
III 77.3%). Futhermore, there was a signiﬁcant correlation
between HIF-1α and HIF-2α (r = 0.27, P<0.001), but no
other signiﬁcant association was found among the markers
(Table 2).
4.4. Univariate Analyses. Table 1 summarizes the prognostic
impact of the clinicopathological variables. Age (P = 0.030),
patient nationality (P = 0.014), histological entity (P =
0.003), tumor size (P = 0.019), malignancy grade (P<
0.001), tumor depth (P = 0.002), surgery (P<0.001), and
surgical margins (P<0.001) were signiﬁcant prognostic
indicators for DSS.
Amongtheexaminedmolecularmarkers,hightumorcell
GLUT-1 expression (P<0.001) and HIF-2α expression (P =
0.021) correlated signiﬁcantly with a poor DSS (Table 3 and
Figure 2).
Subgroupanalyseswithrespecttohistologyandresection
margins were done for all markers, but due to a low
number of cases many results only tended to be signiﬁcant.
However, GLUT1 became a signiﬁcant prognostic marker in
pleomorphic sarcomas (P = 0.02). The prognostic impact
of GLUT1 was not statistically signiﬁcant in patients with
nonwide resection margins, but signiﬁcant in patients with
wide resection margins (P = 0.001).
4.5. Multivariate Cox Proportional Hazards Analyses. Results
fromthemultivariateanalysisarepresentedinTables1and3.
High malignancy grade (P<0.001), deep tumor depth (P =
0.045), no surgery (P<0.001), nonwide resection margins
(P<0.001), and high GLUT-1 expression were signiﬁcant
independent negative prognostic indicators of DSS.
5. Discussion
In this large-scale non-GIST STSs TMA analysis, we inves-
tigated the prognostic impact of HIF-1α,H I F - 2 α,a n d
the metabolic HIF-regulated GLUT-1 and CAIX. Interest-
ingly, high GLUT-1 expression is an independent negative
prognostic factor in non-GIST STSs, while high HIF-2α
expression is signiﬁcantly associated with a poor prognosis
in univariate analyses.
GLUT-1 is extensively expressed in several tumors [19,
20]. Furthermore, GLUT-1 has been correlated with a dismal
prognosis in diﬀerent cancer types, such as ovarial cancer
[21], nonsmall cell lung cancer (NSCLC) [23], and colorectal
cancer [22]. With respect to sarcoma, Ahrens et al. reported
immunohistochemical GLUT-1 expression in 247 soft tissue
and bone neoplasms [37]. GLUT-1 expression was seen in
a wide variety of both benign and malignant mesenchymal
tumors although they did not assess the prognostic impact
of these markers.
AlsoinsarcomashasthefunctionofGLUT-1beenrelated
to glucose metabolism. In a prospective evaluation using
a[ 18F]ﬂuorodeoxyglucose positron emission tomography
(FDG-PET), Tateishi and coworkers observed that GLUT-
1 expression and enhanced glucose metabolism were asso-
ciated with tumour grade in bone and soft tissue sarco-
mas [39]. GLUT-1-positive tumors had signiﬁcantly higher6 Sarcoma
Table 2: Correlation between expression of hypoxic markers and clinicopathological variables.
GLUT-1 HIF-1α HIF-2α CAIX
GLUT-1 r = 0.08 r = 0.11 r = 0.18
P = 0.29 P = 0.12 P = 0.013
HIF-1α r = 0.08 r = 0.27 R = 0.18
P = 0.29 P < 0.001 P = 0.013
HIF-2α r = 0.11 r = 0.27 r = 0.17
P = 0.12 P< 0.001 P = 0.017
CAIX r = 0.18 r = 0.18 r = 0.17
P = 0.013 P = 0.013 P = 0.017
Age r = 0.12 r = 0.15 r =− 0.04 r =− 0.02
P = 0.11 P = 0.93 P = 0.58 P = 0.74
Gender r = 0.13 r =− 0.001 r = 0.07 r = 0.10
P = 0.07 P = 0.97 P = 0.30 P = 0.17
Patient nationality r =− 0.03 r =− 0.15 r = 0.17 r = 0.001
P = 0.67 P = 0.03 P = 0.02 P = 0.97
Histological entity r = 0.08 r =− 0.05 r =− 0.06 r =− 0.03
P = 0.30 P = 0.49 P = 0.43 P = 0.66
Tumor localization r = 0.09 r =− 0.02 r = 0.03 r = 0.19
P = 0.23 P = 0.74 P = 0.69 P = 0.006
Tumor size r = 0.04 r =− 0.004 r = 0.01 r =− 0.01
P = 0.59 P = 0.95 P = 0.85 P = 0.92
Malignancy grade r = 0.35 r =− 0.01 r = 0.23 r = 0.13
P< 0.001 P = 0.85 P = 0.001 P = 0.06
Tumor depth r = 0.10 r = 0.07 r =− 0.05 r = 0.03
P = 0.19 P = 0.33 P = 0.49 P = 0.71
Resection margins r =− 0.10 r =− 0.13 r =− 0.13 r =− 0.05
P = 0.18 P = 0.06 P = 0.07 P = 0.49
r = correlation coeﬃcient.
Table 3: Tumor expression GLUT-1, HIF-1α,H I F - 2 α, and CAIX and their prognostic relevance for disease-speciﬁc survival in 206 patients
with non-gastrointestinal soft tissue (univariate analyses; log-rank test, multivariate analyses; Cox proportional hazards model).
Characteristics
Univariate analyses Multivariate analyses∗
Patients
(n)
Patients
(%)
Median survival
(months)
5-year survival
(%) P HR 95% CI P
GLUT-1 <0.001
Low expression 110 53 NR 64 1.000
High expression 83 40 28 42 1.697 1.083–2.659 0.021
Missing 13 6
HIF-1α 0.658
Low expression 77 37 91 54
High expression 123 60 80 54
Missing 6 3
HIF-2α 0.032
Low expression 66 32 NR 62 1.000
High expression 135 66 59 49 0.965 0.581–1.603 0.892
Missing 5 2
CAIX 0.067
Low expression 44 21 NR 65
High expression 162 79 58 50
NR: not reached.
∗Only signiﬁcant variables from the univariate analyses were entered into the multivariate analyses.Sarcoma 7
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Figure 2: DSS curves according to GLUT-1 (a), HIF-1α (b), HIF-2α (c) and CAIX (d) expression in non-GIST STS. DSS: disease-speciﬁc
survival, GLUT-1: glucose transporter-1, HIF-1/2α: hypoxia induced factor 1/2α, CAIX: carbonic anhydrase IX, and non-GIST STS: non-
gastrointestinal stromal tumor soft tissue sarcomas.
mean and maximal standardized uptake values (SUVs) than
the GLUT-1-negative tumors. Likewise, Nagamatsu et al.
reported the use of FDG-PET for diagnosis of uterine
sarcomas[40].TheydetectedGLUT-1expressionscorestobe
signiﬁcantlyhigherinsarcomasandendometrialcancerthan
in leiomyomas and concluded that immunohistochemical
examination of GLUT-1 conﬁrmed the high FDG uptake in
leiomyosarcoma patients.
The prognostic impact of GLUT-1 has been documented
by Endo and coworkers [38]. They reported GLUT-1 expres-
sion in 22 patients with bone sarcomas and 45 with STS.
TheyfoundGLUT-1overexpressioninasmuchas83%ofthe
patients. The patients with GLUT-1 overexpression showed
signiﬁcantly worse OS compared with those without (P =
0.029). Possibly due to the small number of cases, GLUT-1
did not appear as an independent prognostic factor in their
study. Herein we document for the ﬁrst time that GLUT-1
expression is an independent indicator of poor prognosis in
non-GIST STSs.
Overexpression of HIF-2α was associated with reduced
survival in the univariate analysis. To our knowledge, this
is the ﬁrst report to examine HIF-2α in sarcoma patients.
Theseresultsare,however,comparablewithﬁndingsinother
tumors. Koukourakis and colleagues found that HIF-2α and
CAIX were associated with radiotherapy failure in head and
neckcancerpatients[33].Likewise,HIF-1αandHIF-2αwere
highly expressed in metastatic gastric cancers and correlated
signiﬁcantly with clinical stage [41].
In our study, HIF-1α overexpression was not associated
with inferior survival, which is in contrast to the ﬁndings by
Shintani et al. [42]. They reported IHC expression of HIF-1α
in 49 specimens of STS and found strong and moderate HIF-
1α expression to be independently associated with a shorter
survival.
For the prognostic impact of HIF-2α, several reports are
consistent with our results. Yoshimura et al. examined HIF-
1α and HIF-2α expression in 87 resected colorectal carcino-
mas [43]. HIF-1α (45%) was more frequently expressed than
HIF-2α(30%),butclinicopathologicalvariablesrepresenting
tumor aggressiveness correlated more often with HIF-2α,
than HIF-1α. In lung cancer, Giatromanolaki and coworkers
[44]f o u n dt u m o rH I F - 2 α-expression, not HIF-1α,t ob e
independentlyassociatedwithsurvival.Furthermore,asIHC
is a “snapshot” of the tissue metabolism, involved molecules8 Sarcoma
may not be expressed at high level simultaneously. HIFs are
also known to be rapidly degraded [7] and diﬀerentially
expressed during prolonged hypoxia [45, 46]. Other tran-
scription factors may also be involved, hence blurring the
clear-cut image we have of hypoxia pathways [47, 48].
In our study, CAIX tended towards a negative prognostic
impactintheunivariateanalysis.Incentralchondrosarcoma,
the only sarcoma in which CAIX has been studied, Boeuf et
al. reported CAIX reactivity to be a grade-independent pre-
dictor of poor metastasis-free survival [49]. The results from
other malignancies are divergent. Woelber et al. found CAIX
to be upregulated in ovarian cancer [50]. Serum concentra-
tionofCAIXshowed,however,nosigniﬁcantchangesduring
ﬁrst-line therapy, and there was no association between
serumCAIXandprogression-freeoroverallsurvival.Inrenal
cell carcinoma, CAIX is strongly expressed and associated
with clinical outcome, but not as an independent prognostic
marker [51]. An independent prognostic impact of CAIX
was, however, observed by Lie et al. in NSCLC [52]. More
intriguing is the data from Eckert et al. in oral squamous
cell carcinoma [53], where patients with low coexpression of
HIF-1α/CAIX indicated a good prognosis, whereas patients
with increased HIF-1α and low CAIX expression had around
5-fold increased risk of tumor-related death (P = 0.042).
A st h i si sar e t r o s p e c t i v es t u d y ,n o n eo ft h et u m o r sw e r e
available for in vivo analysis. Hence, no ﬁrm conclusions
regardingthesefactorsassociationtoactualhypoxiaitselfcan
bedrawn.In vivo hypoxia canonlybe measureddirectlywith
electrodes on tumors available for such instrumentation,
indirectly by PET using nitroimidazole compounds or newer
speciﬁc tracers like F-FAZA (Fluorine-ﬂuoroazomycin arabi-
noside)orF-EF5(Fluorine2-(2-nitro-1H-imidazol-1-yl)-N-
(2,2,3,3,3-pentaﬂuoropropyl)-acetamide) [54]. In addition,
it is the hypoxia in vivo that is clinically important since
absolute hypoxia initiates when the tumor blood ﬂow is
terminated under surgery. It also has to be kept in mind that
it usually takes hours until the tissues are ﬁxed in formalin
[55]. In this study we have instead explored the impact of
hypoxia indirectly by evaluating proposed hypoxic markers
due to their up regulation by hypoxia [8], although their role
is controversial [10].
It is possible to question the heterogeneity of the patient
population,regardingorigin,histology,andtreatment.How-
ever, this is the limitation for almost all studies on seldom
malignancies such as STS. Furthermore, GLUT-1 had the
same tendency in all subgroups in our material.
Another potential limitation with TMA is the eventual
lack of homogeneous expression that is easily identiﬁed in
larger tissue sections. Hence, to conﬁne the impact of this
issue, we used duplicate cores which were selected to be as
representative as possible. Up to 95% correlation has been
demonstrated when comparing tumour cell assessment in
duplicate 0.6mm cores versus the whole slide [56].
In cancer therapy there is an increasing focus on person-
alized therapy. This shift is associated with the introduction
of novel cytotoxic agents and molecular targeted drugs.
Inhibitors of HIF-1 and CAIX have been developed and are
currently under examination [57–59]. Increased knowledge
about hypoxia-associated markers and metabolic markers in
non-GIST-STSwillbevitalinidentifyingdiﬀerenttumorcell
phenotypes as candidates for speciﬁc molecular targeting.
Though further studies are needed, GLUT-1 appears as a
potentially relevant prognostic factor in routine examination
in non-GIST-STS. The identiﬁcation of independent prog-
nostic markers in STS and other malignancies is vital for the
future development of new molecular targeted drugs.
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